Figure 3
Figure 3. Pharmacokinetics of rFVIII and rFVIII-PEG-Lip in HemA mice. (A) A representative plasma PK profile. In this experiment, HemA mice received either 116 IU/kg rFVIII (●) or 70 IU/kg rFVIII-PEG-Lip (). Citrated blood was collected at 5 minutes, and 4, 8, 16, 24, 32, and 48 hours after tail vein injection. Plasma FVIII activities were measured by Coatest. Results presented are mean from 5 mice/treatment at each time point. The decay curves were fitted by noncompartmental model with sparse sampling in WinNonLin. (B-C) HemA mice were dosed with 1.5 IU (2 × 105 cpm)/mouse of 125I-rFVIII reconstituted in buffer (●) or PEG-Liposome (). The decay of 125I-FVIII in both whole blood (B) and platelet-poor plasma (C) was monitored at 5 minutes, 30 minutes, and 1, 4, 8, 16, 24, 48, 72, and 96 hours. Results presented are individual gamma count from 5 mice at each time point for each treatment. The decay curves were fitted using 2-compartmental model in WinNonLin.

Pharmacokinetics of rFVIII and rFVIII-PEG-Lip in HemA mice. (A) A representative plasma PK profile. In this experiment, HemA mice received either 116 IU/kg rFVIII (●) or 70 IU/kg rFVIII-PEG-Lip (). Citrated blood was collected at 5 minutes, and 4, 8, 16, 24, 32, and 48 hours after tail vein injection. Plasma FVIII activities were measured by Coatest. Results presented are mean from 5 mice/treatment at each time point. The decay curves were fitted by noncompartmental model with sparse sampling in WinNonLin. (B-C) HemA mice were dosed with 1.5 IU (2 × 105 cpm)/mouse of 125I-rFVIII reconstituted in buffer (●) or PEG-Liposome (). The decay of 125I-FVIII in both whole blood (B) and platelet-poor plasma (C) was monitored at 5 minutes, 30 minutes, and 1, 4, 8, 16, 24, 48, 72, and 96 hours. Results presented are individual gamma count from 5 mice at each time point for each treatment. The decay curves were fitted using 2-compartmental model in WinNonLin.

Close Modal

or Create an Account

Close Modal
Close Modal